To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:6 Issue:10 Number:19 ISSN#:2564-2537
ACE Report #9418
Ace Report Cover Trauma

Effects of teriparatide versus risedronate following pertrochanteric fracture fixation

How to Cite

OrthoEvidence. Effects of teriparatide versus risedronate following pertrochanteric fracture fixation. ACE Report. 2017;6(10):19. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:2

Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks

J Bone Joint Surg Am. 2016 Nov 16;98(22):1868-1878

Contributing Authors:
S Overgaard F Frihagen P Aspenberg F Marin H Petto J Malouf U Tarantino PA García-Hernández C Corradini JJ Stepan L Borris E Lespessailles K Papavasiliou JR Caeiro

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


224 patients over the age of 50 with a pertrochanteric hip fracture who had undergone fixation were randomized to 26 weeks of daily subcutaneous teriparatide 20ug or weekly oral risedronate 35mg. The purpose of this study was to compare measures of functional and clinical outcome, as well as safety outcomes and fracture healing over a 26-week follow-up. Results demonstrated significantly better Ti...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.